MEDICATION POLICY

Generic Name: Ophthalmic VEGF Inhibitors

Therapeutic Class or Brand Name: Ophthalmic VEGF Inhibitors

Applicable Drugs (if Therapeutic Class):

Avastin® (bevacizumab), Eylea® (aflibercept), Lucentis® (ranibizumab), Macugen® (pegaptanib)

Date of Origin: 8/28/15

Date Last Reviewed/Revised: 3/20/17

GPI Code: 2133502000, 8665501000, 8665505030, 8665506000

Prior Authorization Criteria (may be considered medically necessary when criteria I through III are met):

I. Documented diagnosis of one of the following conditions A through E AND must meet criteria listed under applicable diagnosis:

A. Neovascular (Wet) Age-Related Macular Degeneration (AMD) AND one of criteria 1 through 4 is met:
   1. Request is for Avastin®.
   2. Request is for Eylea® AND criterion a is met:
      a. Documented trial and failure of, intolerance to, or contraindication to Avastin®.
   3. Request is for Lucentis® AND criterion a is met:
      a. Documented trial and failure of, intolerance to, or contraindication to Avastin® and Eylea®.
   4. Request is for Macugen® AND criterion a is met:
      a. Documented trial and failure of, intolerance to, or contraindication to TWO of the following: Avastin®, Eylea®, and Lucentis®.

B. Diabetic Macular Edema (DME) AND one of criteria 1 through 4 is met:
   1. Request is for Avastin®.
   2. Request is for Eylea® AND one of the following criteria a or b is met:
      a. Documented baseline visual acuity of 20/50 or worse.
      b. Documented trial and failure of, intolerance to, or contraindication to Avastin®
   3. Request is for Lucentis® AND criterion a is met:
      a. Documented trial and failure of, intolerance to, or contraindication to Avastin® and Eylea®.
   4. Request is for Macugen® AND criterion a is met:

Disclaimer: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgment in providing the most appropriate care for their patients.

Confidential & Proprietary, Ventegra, Inc.
MEDICATION POLICY

a. Documented trial and failure of, intolerance to, or contraindication to TWO of the following: Avastin®, Eylea®, and Lucentis®.

C. Macular Edema Following Retinal Vein Occlusion (RVO) AND one of criteria 1 through 3 is met:
   1. Request is for Avastin®.
   2. Request is for Eylea® AND criterion a is met:
      a. Documented trial and failure of, intolerance to, or contraindication to Avastin®
   3. Request is for Lucentis® AND criterion a is met:
      a. Documented trial and failure of, intolerance to, or contraindication to Avastin® and Eylea®

D. Diabetic Retinopathy (DR) in Patients with DME AND one of criteria 1 through 3 is met:
   1. Request is for Avastin®.
   2. Request is for Eylea® AND criterion a is met:
      a. Documented trial and failure of, intolerance to, or contraindication to Avastin®
   3. Request is for Lucentis® AND criterion a is met:
      a. Documented trial and failure of, intolerance to, or contraindication to Avastin® and Eylea®

E. Myopic Choroidal Neovascularization (mCNV) AND one of criteria 1 or 2 is met:
   1. Request is for Avastin®.
   2. Request is for Lucentis® and criterion a is met:
      a. Documented trial and failure of, intolerance to, or contraindication to Avastin®

II. Minimum age requirement: 18 years old.

III. Provider is an ophthalmologist.

Exclusion Criteria:

- Ocular or periocular infections.
- Concurrent use of one VEGF inhibitor with another VEGF inhibitor.

Other Criteria:

- N/A

Quantity/Days Supply Restrictions:

- Avastin®: One injection every 4 weeks.
- Eylea®:

Disclaimer: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgment in providing the most appropriate care for their patients.
MEDICATION POLICY

- AMD: One injection every 4 weeks for the first 12 weeks, followed by one injection every 8 weeks.
- RVO: One injection every 4 weeks.
- DME/DR: One injection every 4 weeks for the first 5 injections, followed by one injection every 8 weeks.
  - Lucentis®: One injection every 4 weeks.
  - Macugen®: One injection every 6 weeks.

Approval Length:

- Authorization:
  - mCNV:
    - Lucentis®: 3 months.
    - Avastin®: 1 year.
  - AMD, DME, RVO, DR: 1 year.
- Re-Authorization: An updated letter of medical necessity or progress notes showing current medical necessity criteria are met and that the medication is effective. Reauthorization is for the same length as the original authorization.

Appendix:

- N/A

References:


Disclaimer: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgment in providing the most appropriate care for their patients.


Disclaimer: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgment in providing the most appropriate care for their patients.

Confidential & Proprietary, Ventegra, Inc.


Disclaimer: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgment in providing the most appropriate care for their patients.

Confidential & Proprietary, Ventegra, Inc.
40. Medi-Span.

Disclaimer: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgment in providing the most appropriate care for their patients.

Confidential & Proprietary, Ventegra, Inc.
### Historical Tracking Of Changes Made To Policy

<table>
<thead>
<tr>
<th>Date</th>
<th>Change Description</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2. Changed “I. Documented diagnosis of one of the following conditions A through D…” to “I. Documented diagnosis of one of the following conditions A through E…” and added “I. E. Myopic Choroidal Neovascularization (mCNV) AND one of criteria 1 or 2 is met: 1. Request is for Avastin®; 2. Request is for Lucentis® and criterion a is met: a. Documented trial and failure of, intolerance to, or contraindication to Avastin®” under Prior Authorization Criteria.</td>
</tr>
<tr>
<td></td>
<td>3. Changed “Authorization: 1 year; Re-Authorization: An updated letter of medical necessity or progress notes showing current medical necessity criteria are met and that the medication is effective” to “Authorization: mCNV: Lucentis®: 3 months; Avastin®: 1 year; AMD, DME, RVO, DR: 1 year; Re-Authorization: An updated letter of medical necessity or progress notes showing current medical necessity criteria are met and that the medication is effective. Reauthorization is for the same length as the original authorization” under Approval Length.</td>
</tr>
</tbody>
</table>